Consistent with these findings, compared to their TIM-3- counterparts, PD-1+TIM-3+ CD8 T cells from RCC tumors were shown to respond poorly to anti-CD3 and anti-CD28 stimulation as measured by IFNγ secretion. This evidence concerns the gene CD8A and renal cell carcinoma.